Associated hormonal declines in aging: DHEAS.
DHEA and its sulfate prohormone DHEAS are the most abundant circulating adrenal steroid hormones in humans. DHEA exerts its actions on peripheral target tissues either indirectly, following its conversion to androgens, estrogens or both, or directly, as a steroid hormone interacting with either a nuclear or a membrane receptor. In humans, DHEA shows a characteristic pattern of secretion throughout life. Serum DHEA concentrations decline with advancing age and vary with gender, ethnicity, and environmental factors. Epidemiological studies show an inverse relationship between plasma DHEA(S) levels in men and age-related illnesses, including cardiovascular and metabolic diseases, immune disorders, malignancies, and neurological dysfunction. This has generated great interest on the putative role of DHEA in age-associated illnesses. Administration of DHEA to rats and mice reduces visceral fat accumulation, and improves insulin resistance in experimental models of diet-induced obesity and/or Type 2 diabetes. In addition, recent studies in vitro have shown that DHEA has the capacity to improve endothelial function by increasing nitric oxide (NO) synthesis. Replacement of DHEA in patients with adrenal insufficiency has been shown to exert beneficial effects on well-being, mood, and sexuality. By contrast, in healthy individuals, the physiological age-associated decline in circulating DHEA(S) per se does not justify DHEA supplementation, since the effects of this hormone on metabolic abnormalities, endothelial function in vivo, and cardiovascular events are contradictory. However, these results do not exclude the possibility that DHEA treatment may prove beneficial in specific subgroups of elderly subjects.
Perrini
S
S
Section of Internal Medicine, Endocrinology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
Laviola
L
L
Natalicchio
A
A
Giorgino
F
F
D000309:Adrenal Insufficiency; D000339:Affect; D000375:Aging; D000818:Animals; D001823:Body Composition / Q000187:drug effects; D015519:Bone Density; D019314:Dehydroepiandrosterone Sulfate / Q000008:administration & dosage / Q000097:blood* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2; D004730:Endothelium, Vascular / Q000187:drug effects; D020249:Hormone Replacement Therapy; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D009369:Neoplasms; D009765:Obesity
D019314:Dehydroepiandrosterone Sulfate